Definitive Healthcare Q2 FY 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $55.2 million, down 9% year-over-year.

Adjusted EBITDA: $14.6 million, representing a 26% margin, slightly above guidance.

Adjusted Net Income: $7.5 million, or $0.05 per share.

Unlevered Free Cash Flow: Approximately $50 million over the trailing 12 months.

Subscription Revenue: $52.8 million, also down 9% year-over-year.

Net Dollar Retention Rate: Improved year-over-year for the second consecutive quarter.

Deferred Revenue: $89 million, down 12% year-over-year.

2Strategic Updates and Business Highlights

Core Growth Initiatives: Focused on data differentiation, seamless integrations, customer success, and innovation.

Data Differentiation: Continued investment in proprietary data and AI to enhance data collection and quality.

Customer Engagement: Notable win-back of former customers across various segments, indicating strong value in data quality and service.

Turbo Launch: Introduction of an AI-powered healthcare intelligence platform aimed at improving customer decision-making and engagement, with a pilot program underway.

Operational Efficiency: Over 50% increase in integrations year-over-year, reducing integration time significantly.

3Forward Guidance and Outlook

Q3 2026 Revenue Guidance: Expected between $54 million and $55 million, reflecting an 8% to 10% decline year-over-year.

Full-Year 2026 Revenue Guidance: Revised to $220 million to $222 million, an 8% to 9% decline year-over-year.

Profit Guidance: Adjusted operating income expected between $45.5 million and $47.5 million, with adjusted EBITDA between $57 million and $59 million, improving the midpoint of profit guidance.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Continued year-over-year revenue decline, particularly in the life sciences segment, which is slower to recover.

Professional Services Underperformance: Weaker bookings in traditional analytics engagements, impacting Q3 expectations.

Deferred Revenue and Performance Obligations: Declines in deferred revenue and remaining performance obligations indicate a shift towards shorter-term contracts.

Market Environment: Uncertainty in large pharma commercialization budgets and overall market conditions remain muted.

5Notable Q&A Insights

Turbo Revenue Impact: No significant revenue impact from Turbo anticipated in 2026; expected to influence customer retention during renewal periods.

Life Sciences Segment: Some normalization in claims data, but overall life sciences spending remains cautious. Encouraging new business wins noted, but no significant change in large pharma budgets observed.

Multi-Year Contracts: No substantial shift back to multi-year deals expected; current market conditions favor single-year contracts. Overall, while Definitive Healthcare is managing expenses effectively and making strides in customer retention and product innovation, it faces challenges with declining revenues and a cautious market environment. The company remains focused on strategic initiatives that could position it for future growth.